Lovastatin Tablet
Product Images NDC 83209-143

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 83209-143). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Boswell Pharmacy Services Llc D/b/a Bps Wholesale, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lovastatin 40mg (30)

Lovastatin USP 40 mg tablet packaging label from Boswell Pharmacy Services LLC d/b/a BPS Wholesale. The label specifies a quantity of 30 tablets, prescription only, with storage instructions between 20-25°C (68-77°F) and permitted excursions from 15-30°C (59-86°F). Includes batch number, lot example, NDC 83209-143-30, and repackaging site in Jennerstown, PA.*

FDA Label Image

Structural Formula (Lov00 0004 01)

Chemical structure diagram of Lovastatin active ingredient showing its molecular arrangement and bonding pattern.*

FDA Label Image

Table I (Lov00 0004 02)

A data table titled 'The Effect of Other Drugs on Lovastatin Exposure When Both Were Co-administered' detailing the number of subjects, dosing of coadministered drugs or grapefruit juice, dosing of Lovastatin, and AUC ratios for Lovastatin and Lovastatin acid. The table includes drugs such as Gemfibrozil, Itraconazole, Grapefruit Juice (high and low dose), Cyclosporine, and Diltiazem with corresponding dosing regimens and effects on Lovastatin exposure.*

FDA Label Image

Figure 1 (Lov00 0004 03)

A line graph titled 'Acute Major Coronary Events (Primary Endpoint)' showing the proportion of participants without event over six years of follow-up. Two lines compare Lovastatin and Placebo groups, indicating a 37% risk reduction with Lovastatin (p<0.001). The vertical axis represents the proportion of participants without event, ranging from 0.90 to 1.00.*

FDA Label Image

Table Vii (Lov00 0005 04)

A data table titled 'Table VII Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis' lists interacting agents such as strong CYP3A4 inhibitors, HIV protease inhibitors, gemfibrozil, cyclosporine, danazol, diltiazem, dronedarone, verapamil, amiodarone, and grapefruit juice, alongside prescribing recommendations for lovastatin, including contraindications and dosage limits.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.